Key clinical point: Galcanezumab has clinical benefits for patients with migraine and medication overuse.
Major finding: Among patients with medication overuse who received galcanezumab, 85% of those with episodic migraine and 50% of those with chronic migraine had a reduction in medication overuse.
Study details: A post hoc analysis of 1,285 patients with migraine and medication overuse in three phase 3 studies of galcanezumab.
Disclosures: The investigators are employees of Eli Lilly, which developed galcanezumab and funded the studies.
Aurora S et al. AHS 2019. Abstract IOR07.